Seth Klarman · Q2 2019
Baupost Group
Portfolio at the end of Q2 2019, from the 13F filed August 13, 2019. See the filing on EDGAR ↗
| Company | Weight | Held since | Change |
|---|---|---|---|
| Liberty Global LBTYK · history | 10.1% | Q3 2018 | Add 7% |
| Viasat VSAT · history | 10.0% | Q2 2013 or earlier | No change |
| Fox Corporation FOXA · history | 9.1% | Q1 2019 | No change |
| eBay EBAY · history | 8.6% | Q4 2018 | Reduce 18% |
| Cheniere Energy LNG · history | 6.6% | Q1 2014 | Reduce 15% |
| Allergan AGN · history | 5.6% | Q1 2016 | Reduce 23% |
| Bristol-Myers Squibb BMY · history | 5.3% | Q1 2019 | Add 225% |
| Qorvo QRVO · history | 5.2% | Q1 2017 | Reduce 18% |
| PG&E PCG · history | 5.1% | Q1 2018 | No change |
| CBS CBS · history | 4.5% | Q4 2018 | Add 17% |
| McKesson MCK · history | 3.2% | Q3 2017 | Reduce 8% |
| Synchrony SYF · history | 2.9% | Q3 2016 | Reduce 35% |
| Tesla TSLA.CV · convertible notes · history | 2.7% | Q1 2018 | No change |
| DigitalBridge CLNY · history | 2.2% | Q2 2018 | No change |
| Univar Solutions UNVR · history | 1.9% | Q3 2018 | No change |
| Fox Corporation FOX · history | 1.9% | Q1 2019 | No change |
| Liberty Global LBTYA · history | 1.8% | Q3 2018 | Add 50% |
| Cencora COR · history | 1.7% | Q3 2017 | Reduce 8% |
| Takeda Pharmaceutical TAK · history | 1.5% | Q1 2019 | Reduce 12% |
| Antero Resources AR · history | 1.4% | Q3 2014 | No change |
| Theravance Biopharma TBPH · history | 1.4% | Q2 2014 | No change |
| Nexstar Media Group NXST · history | 1.3% | Q4 2018 | Add 40% |
| Atara Biotherapeutics ATRA · history | 1.3% | Q4 2014 | Add 10% |
| Akebia Therapeutics AKBA · history | 1.1% | Q4 2018 | No change |
| Translate Bio TBIO · history | 1.0% | Q2 2018 | Add 36% |
| XPO XPO · history | 0.8% | Q2 2019 | Buy |
| Veritiv VRTV · history | 0.6% | Q3 2014 | No change |
| Trilogy Metals TMQ · history | 0.4% | Q2 2013 or earlier | Add 5% |
| Sinclair SBGI · history | 0.3% | Q2 2018 | Reduce 81% |
| Gossamer Bio GOSS · history | 0.2% | Q1 2019 | No change |
| Theravance Biopharma TBPH.CV · convertible notes · history | 0.2% | Q4 2016 | No change |
| Paratek Pharmaceuticals PRTK · history | 0.1% | Q4 2014 | No change |
| 32 positions | 100.0% |
Weight is the position's share of the total value in this 13F, not of the whole fund. Price is the value divided by the number of shares, so it's the price at the end of the quarter, as the firm reported it. Change compares share counts with Q1 2019, adjusted for stock splits.
Sector weighting
| Media & telecom | 38.9% | |
|---|---|---|
| Health care | 22.6% | |
| Consumer discretionary | 11.3% | |
| Energy | 8.0% | |
| Technology | 5.2% | |
| Financials & real estate | 5.2% | |
| Utilities | 5.1% | |
| Industrials | 3.3% | |
| Materials | 0.4% |
What changed from Q1 2019
- Buy XPO XPO 0.8% of the 13F
- Add 7% Liberty Global LBTYK 8.0% → 10.1%
- Add 225% Bristol-Myers Squibb BMY 1.6% → 5.3%
- Add 17% CBS CBS 3.4% → 4.5%
- Add 50% Liberty Global LBTYA 1.0% → 1.8%
- Add 40% Nexstar Media Group NXST 0.9% → 1.3%
- Add 10% Atara Biotherapeutics ATRA 2.1% → 1.3%
- Add 36% Translate Bio TBIO 0.5% → 1.0%
- Add 5% Trilogy Metals TMQ 0.3% → 0.4%
- Reduce 18% eBay EBAY 9.1% → 8.6%
- Reduce 15% Cheniere Energy LNG 7.2% → 6.6%
- Reduce 23% Allergan AGN 5.9% → 5.6%
- Reduce 18% Qorvo QRVO 6.4% → 5.2%
- Reduce 8% McKesson MCK 2.8% → 3.2%
- Reduce 35% Synchrony SYF 3.8% → 2.9%
- Reduce 8% Cencora COR 1.6% → 1.7%
- Reduce 12% Takeda Pharmaceutical TAK 1.8% → 1.5%
- Reduce 81% Sinclair SBGI 0.9% → 0.3%
- Sell Celgene CELG was 3.2%
- Sell Pioneer Natural Resources PXD was 2.6%
- Sell Disney DIS was 0.4%
- Sell GTY Technology GTYH.WS was 0.0%